Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGEN1777 in advanced solid tumors
NCT05025085Phase 1Completed
- Sponsor
- Agenus Inc.
- Start
- Oct 2021
- Primary completion
- Jul 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of AGEN1777 in cancer (2 arms), sponsored by Agenus Inc. Primary endpoints: Dose-Limiting Toxicities at 21 days and Treatment-Emergent Adverse Events at 2 years. Started Oct 2021; status: completed.
02
Drugs
AGEN1777
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05025085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05025085.